Contact
Please use this form to send email to PR contact of this press release:
Kitov Announces Dosing of First Patient in Phase 1/2 Clinical Trial of NT219 in Advanced Cancer Patients
TO:
Please use this form to send email to PR contact of this press release:
Kitov Announces Dosing of First Patient in Phase 1/2 Clinical Trial of NT219 in Advanced Cancer Patients
TO: